Здоровье
Novo weight loss drug trial shows improvement in fatty liver disease
Novo Nordisk said Friday that its weight-loss drug achieved the primary goal of a late-stage study in patients with fatty liver disease, reducing scarring of
EU competition authorities to rule on Novo’s purchase of Catalent by 6 December
EU competition authorities will decide by 6 December whether to approve Novo Holdings’ acquisition of contract drugmaker Catalent, the European Commission said in a document
US FDA cautions against California plant making compounded weight-loss drugs
The U.S. Food and Drug Administration on Friday warned against the use of compounded drugs, including versions of popular weight-loss products made at a California
Novo weight loss drug trial shows improvement in fatty liver disease
Novo Nordisk said Friday that its weight-loss drug achieved the primary goal of a late-stage study in patients with fatty liver disease, reducing scarring of
Novartis CEO ‘very confident’ in his sales plans and not afraid of patent collapse
Novartis CEO Vas Narasimhan said in an interview on Saturday that he expects to increase its annual sales by at least 5 per cent a
Gradual dosing of Lilly drug for Alzheimer’s disease reduces risk of brain swelling
Starting a more gradual dosing schedule for Eli Lilly’s Alzheimer’s disease drug Kisunla reduces the percentage of patients suffering from potentially serious brain swelling, according
GSK warns of declining vaccine sales in 2024 due to lower demand for respiratory syncytial virus vaccines
GSK on Wednesday said sales of its vaccines would fall this year after weaker-than-expected sales results for respiratory syncytial virus (RSV) and shingles vaccines in
WHO says tuberculosis has once again become the leading cause of death from infectious diseases
Tuberculosis has replaced COVID-19 to become the leading cause of death from infectious diseases in 2023, according to a World Health Organisation report released Tuesday
Pfizer benefits from sales of COVID-19 treatments
Pfizer reported higher-than-expected profits due to strong sales of COVID treatment Paxlovid, a major victory for chief executive Albert Bourla as he takes on activist
Straumann sales growth driven by strong demand in the Asia-Pacific region
Swiss dental implant maker Straumann on Tuesday reported double-digit percentage growth in organic revenue for the third quarter as more people seek dental services globally,